New therapeutic strategy for atopic dermatitis by targeting CHI3L1/ITGA5 axis.

Furthermore, the analysis of the reconstructed human skin (RHS) tissue AD model confirmed that CHI3L1-Ab treatment reduced skin inflammation by inhibiting the CHI3L1/NF- B/ITGA5 axis (Figure 3E-I). After confirming that CHI3L1 regulates AD-related skin inflammation, we examined the therapeutic effect of CHI3L1-antibody (Ab). Furthermore, the inhibition of CHI3L1 by CHI3L1-Ab suppresses AD-like symptoms and inflammatory responses by regulating CHI3L1, the NF- B/ITGA5 axis. [Extracted from the article]